Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318507 · ClinicalTrials.gov registry record
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
A clinical trial of Breast Neoplasms, sponsored by Pennington Biomedical Research Center.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06318507: Recruiting study of Breast Neoplasms, sponsored by Pennington Biomedical Research Center.
NCT06318507 is a study of Breast Neoplasms that is actively recruiting participants, run by Pennington Biomedical Research Center. The registered enrollment target is 25 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06318507, a study of Breast Neoplasms, is actively recruiting participants, sponsored by Pennington Biomedical Research Center.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Primary Outcome
Defined as ypT0/Tis ypN0, ypT0 ypN0, and ypT0/Tis
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fecal microbial diversity
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2026-12-31 |
What NCT06318507 shows while recruiting
NCT06318507 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Fecal microbial diversity is the first listed.
NCT06318507 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06318507 about?
NCT06318507 is a clinical study titled "The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy". This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
What is the current status of trial NCT06318507?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-03-11. Estimated completion is 2026-12-31.
What conditions does trial NCT06318507 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT06318507?
The interventions under investigation include: Fecal microbial diversity (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06318507?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06318507 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06318507's enrollment target sits among peer trials
25 90th of 97 higher than 7 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Registry Study of Breast Microseed Treatment
RECRUITING
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI